Thyroid Problems From Immunotherapy — The Commonest Hormone Effect

Thyroid problems are the single most common hormone-related side effect of checkpoint inhibitor immunotherapy — more frequent than pituitary (hypophysitis) or adrenal involvement, per NCCN and ASCO immune-related adverse event (irAE) guidance. A meaningful proportion of patients on PD-1/PD-L1 or CTLA-4 immunotherapy develop some change in thyroid function during treatment, ranging from a mild, silent shift on a blood test to more noticeable overactive or underactive symptoms.

Because it is so common, thyroid function — TSH and free T4 — is checked as a routine blood test before every immunotherapy cycle, whether or not you have symptoms. That routine testing is deliberate: this is exactly the irAE where the report, not how you feel, usually finds the problem first.

This page explains what a common, manageable hormone change looks like — not how to manage a hormone emergency yourself. See the escalation note above and the red-flag list below for when to call instead of reading on.

Symptoms depend on which way the thyroid shifts. An early, often brief overactive phase can bring a fast heartbeat, sweating, anxiety, tremor, or unplanned weight loss. This frequently settles into — or is followed months later by — an underactive phase: fatigue, feeling unusually cold, weight gain, constipation, dry skin, and low mood.

The difficulty is that fatigue, weight change, and low mood are also blamed on the cancer or on treatment itself — which is precisely the angle worth naming plainly: this is a very common, very treatable change that gets missed because its symptoms hide in plain sight among everything else you're already feeling. A routine blood test, not how you feel day to day, is what usually catches it.

Often, yes, for the underactive phase — once the thyroid gland is affected this way, most patients need thyroid hormone replacement for the long term, with the dose set and adjusted by your treating clinician based on periodic blood tests, never self-directed. The earlier overactive phase, by contrast, is frequently transient and either settles on its own or transitions into the underactive phase within a few months.

Either way, this is a manageable, well-understood late effect — not one that stops your cancer treatment. What it is not is a hormone emergency. Watch for these signs, which point to something more serious than a routine thyroid shift and need emergency care instead:

In most cases, immunotherapy continues alongside thyroid management — a thyroid problem is not usually a reason to pause or stop your cancer treatment the way a gut, lung, or liver reaction can be. During an overactive phase, your clinician may use symptom-control medicine while your levels are monitored closely, since this phase is frequently transient.

If the underactive phase develops or persists, your clinician starts and titrates a daily thyroid hormone replacement, adjusting the dose based on repeat TSH and free T4 results over several weeks — this is a clinician-directed process, never a fixed dose or something to self-adjust based on how you feel. For most patients this becomes a stable, long-term daily routine rather than an ongoing concern.

Whether monitoring frequency changes, and for how long replacement continues, is decided case by case by your oncology and endocrinology team based on your trend — never assumed in advance either way.

No — though all three are hormone (endocrine) immune reactions and get confused early on because fatigue is a shared symptom. A thyroid problem is common and generally low-risk, managed with monitoring and, if needed, hormone replacement, as described above. Pituitary inflammation and adrenal insufficiency are far less common but more serious, and need their own careful work-up rather than being assumed to be "just the thyroid."

If your fatigue hasn't improved with thyroid treatment, or comes with other symptoms like headaches or vision change, our companion page on hypophysitis: pituitary inflammation from immunotherapy explains how that is worked up separately. If dizziness, salt craving, or unexplained weight loss are part of the picture, see adrenal insufficiency: the immune effect that can be fatal. And if you're facing the true emergency version of a hormone crisis right now, our page on adrenal crisis: recognising it and what to do immediately explains what to do — call first, read after.

Hormone irAEs are often confused with each other because tiredness is a shared early symptom, which is why we've written each one up separately: see Hypophysitis: Pituitary Inflammation From Immunotherapy and Adrenal Insufficiency: The Immune Effect That Can Be Fatal if your symptoms go beyond a simple thyroid shift, or Adrenal Crisis: Recognising It and What to Do Immediately if you need the emergency picture right now. For the wider picture of how immunotherapy is delivered and monitored at CION, see the immunotherapy overview.